英文药名:Vesicare(Solifenacin succinate Tablet)
中文药名:琥珀酸索利那新片
生产厂家:Astellas制药 药品介绍: 本品由Astellas制药公司研制,2004年8月首次在荷兰,德国,英国,法国及丹麦同步上市。2004年11月获FDA许可。 【药理药效】 本药为选择性M3受体拮抗药。对尿道膀胱M3受体有潜在选择性,可收缩膀胱平滑肌,同时可刺激唾液分泌。与传统抗胆碱药(如托特罗定和奥昔布宁)相比,本药的不良反应(如口干、便秘、视物模糊等)减少,耐受性较好。 【适应症】 本品用于改善膀胱过度活动症引发的尿频、尿急和尿失禁等症状。 【用法用量】 本品的推荐剂量为每日1次,每次1片(5毫克),必要时可增至每日1次,每次2片(10毫克)。本品必须整片用水送服,餐前或餐后均可服用。 Vesicare (Solifenacin) Tablet VESICARE Generic Name and Formulations: Solifenacin succinate 5mg, 10mg; tabs.
Company: Astellas Pharma US, Inc.
Indications for VESICARE: Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Adult Dose for VESICARE: Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment, or concomitant potent CYP3A4 inhibitors (eg, ketoconazole): max 5mg once daily.
Children's Dose for VESICARE: Not established.
Pharmacological Class: Antispasmodic/anticholinergic.
Contraindications: GI or urinary retention. Uncontrolled narrow-angle glaucoma.
Warnings/Precautions: Severe hepatic impairment: not recommended. Bladder outflow obstruction. GI obstructive disorders. Decreased GI motility. Controlled narrow-angle glaucoma. History of QT prolongation. Renal or hepatic insufficiency. Monitor for signs of CNS effects esp. after initiating treatment or dose increases; consider dose reduction or discontinue if occurs. Exposure to high environmental temperature. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions: Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics. Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers.
Adverse Reactions: Anticholinergic effects (eg, dry mouth, constipation, blurred vision), urinary tract infection, nausea, dyspepsia; CNS effects (eg, headache, confusion, somnolence), angioedema (discontinue if occurs); rare: anaphylactic reactions.
Metabolism: Hepatic (CYP3A4). 98% protein bound.
Elimination: Renal (major), fecal (minor).
Generic Availability: NO
How Supplied: Tabs—30, 90 索利那新是最新一代选择性M3受体拮抗剂,是治疗膀胱过度活动症的一线用药。索利那新膀胱选择性在同类药品中最高,对膀胱的亲和力是唾液腺的6.5倍。因此疗效更强,口干等副作用更少。口服索利那新可显著降低患者尿急、尿失禁、夜尿和排尿次数,增加平均每次排尿量,12个月临床完成率达到81.4%,高于口服奥昔布宁(46.2%)和托特罗定(70.6%),耐受性和依从性更好。索利那新半衰期长达45~68小时,可一天一次给药(空腹或餐后),即使患者漏服一次也不会明显影响疗效。 在索利那新治疗的患者中与药物相关的不良反应发生率显著低于托特罗定治疗的患者(11.7%对23.5%,P<0.05),在最常见的副作用口干方面,索利那新组发生率同样显著低于托特罗定组(5.8%对10.4%,P<0.05)。另外,索利那新对M2受体作用弱,心血管系统毒副反应少。 -------------------------------------------------- 注:以下产品不同规格和不同价格,购买以咨询为准! -------------------------------------------------- 产地国家: 美国 原产地英文商品名: VESICARE 10mg/tab 30tabs/bottle 原产地英文药品名: SOLIFENACIN SUCCINATE 原产地英文化合物名称: 1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid 中文参考商品译名: VESICARE 10毫克/片 30片/瓶 中文参考药品译名: 琥珀酸索非那新 中文参考化合物名称: 1-氮杂双环[2.2.2]辛烷-8-基-(1S)-1-苯基-3,4-二氢-1H-异喹啉-2-甲酸酯丁二酸盐 生产厂家中文参考译名: 安斯泰来 生产厂家英文名: ASTELLAS --------------------------------------------------------------- 产地国家: 欧洲共同体国家 原产地英文商品名: VESICARE 5mg/tab 30tabs/bottle 原产地英文药品名: SOLIFENACIN SUCCINATE 原产地英文化合物名称: 1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid 中文参考商品译名: VESICARE 5毫克/片 30片/瓶 中文参考药品译名: 琥珀酸索非那新 中文参考化合物名称: 1-氮杂双环[2.2.2]辛烷-8-基-(1S)-1-苯基-3,4-二氢-1H-异喹啉-2-甲酸酯丁二酸盐 生产厂家中文参考译名: 安斯泰来 生产厂家英文名: ASTELLAS 该药品相关信息网址1: http://www.vesicare.com/ 该药品相关信息网址2: www.drugs.com/vesicare.html 该药品相关信息网址3: www.rxlist.com/vesicare-drug.htm |